Almost a quarter of the world's deaths caused by cerebral thrombosis, cerebral infarction and other cardiovascular and cerebrovascular diseases each year have become a major threat
to human health.
Among them, thrombotic diseases are one of the main representatives, and while the number of patients is increasing every year, the market size of antithrombotic drugs is also expanding
.
According to statistics, the global antithrombotic drug market was only 7.
3 billion US dollars in 2010, and by 2015, the market size expanded to 11.
85 billion US dollars, an increase of 62.
3%.
In China, the antithrombotic drug market has also maintained a relatively stable growth trend, according to the statistics of Yao Rongyun, the peak sales in China's hospital market has reached 34.
8 billion yuan.
It is worth mentioning that the huge market prospects are still attracting domestic pharmaceutical companies to accelerate their entry into the market
.
It is reported that on November 29, the NMPA released the information on the delivery of drug approval documents on November 29, 2022, among which the aspirin enteric-coated tablets of Chongqing Yaoyou Pharmaceutical were successfully approved for marketing, which is deemed to have passed the consistency evaluation
of generic drugs.
On November 21, the website of the State Food and Drug Administration showed that two generic drugs of Lepu Pharmaceutical's newly registered classification were approved for production and regarded as having been evaluated
.
These two products are antithrombotic drugs, of which clopidogrel aspirin tablets are the first imitation, and the sales scale of rivaroxaban tablets in China's three major terminal markets in 2021 exceeded 5 billion yuan
.
It is worth mentioning that three new generic drugs have been added to the antithrombotic drug market this year, namely Hainan Simcere Pharmaceutical's edoxaban tosylate tablets, Chengdu Xinjie Gaoxin's tirofiban hydrochloride injection and Lepu Pharmaceutical's clopidogrel aspirin tablets
.
Among them, on September 19, the website of the State Food and Drug Administration showed that Hainan Simcere Pharmaceutical's 4 generic drugs edoxaban tosylate tablets were approved for production and regarded as having been evaluated, which is the first generic + first domestic evaluation
.
According to public information, edoxaban is a new anticoagulant drug developed by Daiichi Sankyo that can directly act on coagulation factor Xa, which is used to prevent stroke and systemic embolism in adult patients with non-valvular atrial fibrillation, and can also be used to treat adult deep vein thrombosis and pulmonary embolism, as well as prevent recurrence of deep vein thrombosis and pulmonary embolism in adults
.
According to the company's financial report, Edoxaban's global sales reached 189.
4 billion yen in 2021.
In China, the sales growth rate of this variety in the terminal of public medical institutions in China in 2021 was as high as 5527.
67%
In general, at present, many domestic companies are accelerating their entry into the antithrombotic drug industry track, and most of them are seizing the market
through generic drugs.
In this regard, analysts pointed out that in the future, with the continuous expansion of the market demand for antithrombotic drugs, in the field of original drug research, local antithrombotic drug companies will have a lot of room for growth, and it is necessary to accelerate the improvement of independent innovation capabilities to enhance competitiveness
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
